---
author: mike
pubDatetime: 2024-05-02 19:20:17.960000
modDatetime: 
title: Q124 CVS earnings
slug: q124-cvs-earnings
featured: false
ogImage: /assets/images/250_250.png
tags:
  - transcripts
  - earnings
  - healthcare
description: Earnings summary for CVS health
---
### Earnings Results

- **Revenues:** Approximately $88 billion, an increase of about 4% over the prior year's quarter.
- **Adjusted Operating Income:** Approximately $3 billion.
- **Adjusted EPS:** $1.31, which fell short of expectations.
- **Cash Flow from Operations:** $4.9 billion, a decrease from the previous year, primarily due to the timing of Medicare payments.
- **Health Care Benefits Segment Revenues:** Approximately $32 billion, an increase of about 25% year-over-year.
- **Medical Membership:** 26.8 million, up 1.1 million members sequentially.
- **Adjusted Operating Income for Health Care Benefits:** $732 million, reflecting a higher medical benefit ratio.
- **Medical Benefit Ratio:** 90.4%, up 580 basis points from the prior year quarter.

### Future Guidance

- **2024 Adjusted EPS Guidance:** Lowered to at least $7.
- **Health Care Benefits Adjusted Operating Income:** Revised to at least $3.6 billion, down from at least $5.4 billion.
- **2024 Medical Benefit Ratio Expectation:** Approximately 89.8%, an increase of 210 basis points from prior guidance.
- **Health Services 2024 Adjusted Operating Income:** Updated to at least $7 billion, a decrease of about $400 million.
- **Pharmacy & Consumer Wellness 2024 Adjusted Operating Income:** Expected to remain at least $5.6 billion.
- **2024 Share Count:** Expected to be approximately 1.265 billion shares.
- **2024 Adjusted Tax Rate:** Approximately 25.6%.
- **2024 Cash Flow from Operations:** Revised to at least $10.5 billion.
- **Long-Term Medicare Advantage Margin Target:** Aiming for 4% to 5% margin in 3 to 4 years.

### Trends, Market Conditions, Sentiment

- **Medicare Advantage Pressures:** Significant utilization pressures were experienced, impacting financial results.
- **Cyberattack on Change Healthcare:** Impaired visibility and necessitated a $500 million reserve for estimated unprocessed claims.
- **Market Environment:** Faced with elevated outpatient services and supplemental benefits costs, as well as new pressures in inpatient and pharmacy categories.
- **Medicare Advantage Profitability:** Committed to improving margins despite challenges, including insufficient rates and changes prescribed by the Inflation Reduction Act.
- **Biosimilars Market Initiatives:** Significant progress with biosimilar Humira prescriptions, highlighting strength in CVS Caremark, CVS Specialty, and Cordavis businesses.
- **Consumer Demand:** Noted softening in an uncertain macroeconomic environment but highlighted growth in pharmacy share and interest in new pharmacy models.
- **Enterprise Productivity:** Accelerated initiatives to streamline and optimize operations.
- **Star Ratings Impact:** Improved Star Ratings could provide a $700 million tailwind in 2025 depending on membership retention levels.

### Notable Quotes

- **Karen Lynch:** "Despite the recent challenges in Medicare Advantage, we firmly believe the program can remain a compelling offering for seniors and a very attractive business for Aetna and CVS Health over time."
- **Tom Cowhey:** "Our Health Services segment generated revenue of approximately $40 billion, a decrease of nearly 10% year-over-year... This decrease was partially offset by pharmacy drug mix, growth in specialty pharmacy and the acquisitions of Oak Street Health and Signify Health."
- **Karen Lynch on Future Outlook:** "The current environment does not diminish our opportunities, our enthusiasm, or the long-term earnings power of our company."
